Literature DB >> 31897076

Microbial Contamination of Neonatal Injectable Lipid Emulsions at 12 and 24 Hours' Infusion Time With Evaluation of Infection Control Measures.

Eman A Omran, Faten F Eisa, Wafaa M K Bakr.   

Abstract

OBJECTIVES: This study aimed to assess the microbial contamination rate of injectable lipid emulsion (ILE) repackaged syringes at 12 and 24 hours of their infusion time. Probable risk factors associated with contamination of the ILEs were also assessed. In addition, the antimicrobial resistance pattern of the bacterial isolates was also determined.
METHODS: Samples of ILE were collected from 152 repackaged syringes and their infusion lines after 12 hours and 24 hours of infusion time (73 and 79 samples, respectively). Samples were cultured, the isolates were identified, and the antimicrobial resistance pattern of the bacterial isolates was identified. A checklist was completed throughout the study to observe the compliance to infection control measures by pharmacists (who prepare) and nurses (who administer) the ILE infusions. Results of septic neonatal cultures were taken from records.
RESULTS: Microbial contamination was found in 15.8% of ILE samples. The 2 most common pathogens found among positive samples were Klebsiella pneumoniae (29.2%) and Candida albicans (20.8%). Microbial contamination of repackaged syringes increased from 9.6% at 12 hours to 21.5% at 24 hours. This difference was found to be statistically significant (p = 0.044). A similar trend of predominance of those 2 pathogens, in both ILE and neonatal cultures, was observed. There was a statistically significant better performance of infection control measures of pharmacists rather than nurses. The K pneumoniae isolates (n = 7) showed antibiotic resistance in the following pattern: gentamicin (71.4%), cefazolin (85.7%), and cefoxitin (85.7%).
CONCLUSIONS: The rate of ILE contamination was less at 12 hours' than at 24 hours' infusion time. However, contamination rates at 12 hours were unacceptably high. Klebisella pneumoniae and C albicans were the most common pathogens isolated from ILE. Compliance with infection control measures was significantly worse among nurses compared with pharmacists. Copyright Published by the Pediatric Pharmacy Association. All rights reserved. For permissions, mhelms@pediatricpharmacy.org 2020.

Entities:  

Keywords:  antimicrobial resistance; infection control; injectable lipid emulsions; neonates; parenteral nutrition

Year:  2020        PMID: 31897076      PMCID: PMC6938288          DOI: 10.5863/1551-6776-25.1.53

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  24 in total

1.  Sterility of intravenous fat emulsion in plastic syringes.

Authors:  Pamela Dee Reiter
Journal:  Am J Health Syst Pharm       Date:  2002-10-01       Impact factor: 2.637

2.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

3.  Microbial growth in neonatal intravenous fat emulsion administered over 12 versus 24 hours.

Authors:  Bethany M Dedonato; Lisa I Bickford; Ryan J Gates
Journal:  J Pediatr Pharmacol Ther       Date:  2013-10

4.  Medium-chain triglycerides inhibit growth of Malassezia: implications for prevention of systemic infection.

Authors:  C Papavassilis; K K Mach; P A Mayser
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

Review 5.  Intravenous Lipid Emulsions in Parenteral Nutrition.

Authors:  Gillian L Fell; Prathima Nandivada; Kathleen M Gura; Mark Puder
Journal:  Adv Nutr       Date:  2015-09-15       Impact factor: 8.701

6.  A randomized trial of 72- versus 24-hour intravenous tubing set changes in newborns receiving lipid therapy.

Authors:  A G Matlow; I Kitai; H Kirpalani; N H Chapman; M Corey; M Perlman; P Pencharz; S Jewell; C Phillips-Gordon; R Summerbell; E L Ford-Jones
Journal:  Infect Control Hosp Epidemiol       Date:  1999-07       Impact factor: 3.254

7.  Association of intravenous lipid emulsion and coagulase-negative staphylococcal bacteremia in neonatal intensive care units.

Authors:  J Freeman; D A Goldmann; N E Smith; D G Sidebottom; M F Epstein; R Platt
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

8.  A.S.P.E.N. parenteral nutrition safety consensus recommendations.

Authors:  Phil Ayers; Stephen Adams; Joseph Boullata; Jane Gervasio; Beverly Holcombe; Michael D Kraft; Neil Marshall; Antoinette Neal; Gordon Sacks; David S Seres; Patricia Worthington
Journal:  JPEN J Parenter Enteral Nutr       Date:  2013-11-26       Impact factor: 4.016

9.  Effect of 24-hour intravenous tubing set change on the sterility of repackaged fat emulsion in neonates.

Authors:  Pamela D Reiter; Janie Robles; Elaine B Dowell
Journal:  Ann Pharmacother       Date:  2004-08-24       Impact factor: 3.154

10.  Sudden Deaths of Neonates Receiving Intravenous Infusion of Lipid Emulsion Contaminated with Citrobacter freundii.

Authors:  Ji Yun Bae; Chang Kyung Kang; Su Jin Choi; Eunyoung Lee; Pyoeng Gyun Choe; Wan Beom Park; Nam Joong Kim; Eui Chong Kim; Myoung Don Oh
Journal:  J Korean Med Sci       Date:  2018-03-05       Impact factor: 2.153

View more
  2 in total

1.  Role of environmental surfaces and hands of healthcare workers in perpetuating multi-drug-resistant pathogens in a neonatal intensive care unit.

Authors:  Marwa A Elkady; Wafaa M K Bakr; Hesham Ghazal; Eman A Omran
Journal:  Eur J Pediatr       Date:  2021-09-06       Impact factor: 3.183

2.  Evaluation of a diluted lipid emulsion solution as a lubricant for improved peripherally inserted central catheter guidewire removal in a neonatal population.

Authors:  Matheus F P T van Rens; Ratheesh Paramban; Airene L V Francia; Prem Chandra; Mohamad Adnan Mahmah; Ulrich H Thome; Mohammad A A Bayoumi; Timothy R Spencer
Journal:  BMC Pediatr       Date:  2022-01-31       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.